Prescription drug abuse (PDA) — intentionally taking medication for reasons other than those prescribed — is considered a growing public health crisis in Canada. With support from Health Canada, CIHI is developing a coordinated pan-Canadian approach to prescription drug use monitoring, surveillance and reporting.Initially, we are focusing on 3 drug classes: opioids, benzodiazepines and stimulants.
In collaboration with federal and provincial/territorial governments and expert stakeholders, such as the Canadian Centre on Substance Abuse and chief coroners, CIHI is working to
- Identify data and information needs for prescription drug use surveillance
- Develop pan-Canadian standards to guide data collection
- Establish indicators and metrics for public reporting
- Produce analyses that measure the prevalence, consumption and potential harms of prescription drug use
- Produce resources to support stakeholder understanding and use of data
CIHI is establishing a series of metrics to support prescription drug use surveillance and reporting. The first baseline metrics under consideration include the following:
- Number of Hospital Admissions Due to Opioid Poisonings
- Number of Emergency Department Visits Due to Opioid Poisonings
- Number Receiving Opioids per 1,000 Population
- Number of Defined Daily Doses (DDDs) of Opioids per 1,000 Population
- Number of Non-Natural Opioid-Related Deaths
CIHI and its partners are actively collecting data to report these metrics and will publish the results when they are available. Additional metrics will be identified and refined through expert engagement and will be added to this list when ready.
- Hospitalizations and Emergency Department Visits Due to Opioid Poisoning in Canada
- The number of opioid prescriptions has tripled in Canada over the past decade, but few studies have investigated the impact on health care resources. This report identifies the number of emergency department visits and hospitalizations that are due to opioid poisoning, including provincial/territorial trends and a description of patient demographics and clinical characteristics.
- Data and Information Related to the Monitoring and Surveillance of Prescription Drug Use
- This report summarizes a range of publicly available information related to the monitoring and surveillance of opioids, benzodiazepines and stimulants.
- Part 1: Federal Departments, Agencies and Publicly Funded Pan-Canadian Organizations (available winter 2016–2017)
- CIHI has data holdings that support prescription drug use surveillance. Details are available in these publications:
- Data on provincial/regional hospital mental health services
Partnerships and collaboration
CIHI works with key stakeholders to identify and address prescription drug use information needs, and to foster alignment across health systems. Learn more about some of these organizations and their initiatives:
- Health Canada’s Action on Opioid Misuse
- Canadian Centre on Substance Abuse (CCSA)
- Canadian Agency for Drugs and Technologies in Health (CADTH)
- Centre for Addiction and Mental Health (CAMH)
Find out more
Stay up to date with the project’s eNewsletter.
If you wish to subscribe to the eNewsletter or if you have any other questions about the project, please contact us at email@example.com.